Biogen (BIIB) Cash & Equivalents (2009 - 2026)

Biogen's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 53.42% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $1.3 billion (down 53.42% YoY), while the FY2025 annual figure was $3.0 billion, up 26.67% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $1.3 billion, down from $3.4 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $3.9 billion in Q3 2025, with the low at $1.0 billion in Q4 2023.
• The 5-year median for Cash & Equivalents is $2.6 billion (2023), against an average of $2.5 billion.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 69.29% in 2023, then surged 141.84% in 2025.
• Biogen's Cash & Equivalents stood at $3.4 billion in 2022, then sank by 69.29% to $1.0 billion in 2023, then soared by 126.21% to $2.4 billion in 2024, then grew by 26.67% to $3.0 billion in 2025, then plunged by 57.29% to $1.3 billion in 2026.
• Business Quant data shows BIIB's Cash & Equivalents at $1.3 billion in Q2 2026, $3.4 billion in Q1 2026, and $3.0 billion in Q4 2025.